Content
Free Mental Health Assessment
Reviewed by Daniel Z. Lieberman, MD
Written by Lauren Panoff, MPH, RD
Published 08/04/2022
Updated 08/24/2024
Especially with the move towards decriminalizing recreational marijuana use, you might have stopped thinking twice about indulging. But if you’re taking Prozac® (or its generic, fluoxetine), it is important to pause to consider the interactions that occur between Prozac and weed when you mix the two.
As it turns out, the answer to the question, ‘Can you smoke weed on Prozac?,’ is probably not. According to experts, people taking antidepressant medication should avoid cannabis products. Here’s why.
Content
The interaction between Prozac and marijuana involves several complex mechanisms, primarily affecting your central nervous system (CNS).
Prozac falls into a category of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is approved by the Food and Drug Administration (FDA) to treat a variety of mental health-related disorders, including major depressive disorder (MDD), obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder.
SSRIs — a category that also includes prescription drugs like citalopram, escitalopram, and sertraline — increase available levels of a neurotransmitter called serotonin. They do this by preventing the reuptake of any serotonin that’s leftover and floating around in your brain. This helps to keep mood normal and reduces symptoms of depression and anxiety.
Next, let’s move on to how marijuana works on its own.
The cannabis plant contains chemical compounds called cannabinoids, which interact with your body’s endocannabinoid system. This is the system involved in regulating various physiological processes such as mood, appetite, and pain sensation.
Like other neurotransmitters, cannabinoids have receptors in your brain, which are dedicated areas where these compounds can latch on and cause effects. This includes the psychoactive effects of THC, the psychoactive compound in cannabis responsible for its feelings of altered perception, euphoria, relaxation, and heightened sensory experiences.
Due to these possible effects of cannabis, the drug has been used to help treat chronic pain, anxiety, sleep issues, and inflammation.
So, can you smoke weed on Prozac? While mixing these two compounds won’t create a catastrophic chemical explosion in your brain, using them together isn’t a good idea.
The interaction between Prozac and marijuana is complex and influenced by various factors.
Both substances affect your central nervous system but in different ways. Prozac increases serotonin levels to improve mood and reduce anxiety. Meanwhile, marijuana, particularly its psychoactive component THC, interacts with the endocannabinoid system, influencing mood, perception, and cognition.
As such, combined use of Prozac and weed can lead to enhanced sedation, unpredictable mood changes, and potential health risks like serotonin syndrome, which we’ll cover more next.
Over time, your brain can behave as if it has been taking well beyond the recommended dosage of an SSRI, even though your intake has stayed the same.
The combined use of Prozac and marijuana can be risky.
There are documented case studies dating back to the ‘90s describing the side effects of using the Prozac and weed together. For example, one report discusses increased heart rate and impaired thinking among adolescent boys, and another reviews a manic episode triggered by the combination.
While some people might not experience significant issues, the potential interactions they can have warrant careful consideration and medical guidance.
Read on for some of the reasons why these two don’t make a great pair.
Both Prozac and weed have an impact on your central nervous system. When used together, the combination of the two substances can worsen depression and cause increased sedation, drowsiness, and impaired coordination.
This can heighten the risk of accidents, especially when driving or operating machinery.
While Prozac is used to stabilize mood by regulating serotonin, marijuana's effects on mood can cause a whole range of emotions, including euphoria, relaxation, anxiety, or even panic attacks.
Weed may reduce how well Prozac works by interfering with how it’s metabolized in the body. In some cases, the interaction may make anxiety disorders or paranoia worse, particularly with high-THC strains of marijuana.
According to the National Library of Medicine, cannabinoids can make mood disorders worse. Further, it states that cannabis may be contraindicated in those with mood disorders and psychotic disorders like schizophrenia.
Mania is another potential side effect of both antidepressant medication and cannabis. Recent studies have shown that, as cannabis use has increased, so have cases of mania. While this doesn’t necessarily show cause-and-effect, it does suggest a correlation.
A serious concern with combining Prozac and marijuana is the potential for serotonin syndrome. This condition occurs when there are excess levels of serotonin in the brain, and it can lead to symptoms like agitation, confusion, rapid heartbeat, high blood pressure, muscle rigidity, and fever.
Though rare, serotonin syndrome can be life-threatening, and it requires immediate medical attention. The risk of this, while low, underscores the importance of medical supervision when using these substances together (and with other prescription medications).
Another reason not to mix Prozac and weed is that marijuana can affect the metabolism of Prozac. The CBD contained in marijuana inhibits certain liver enzymes (called CYP450 enzymes) that are responsible for metabolizing many drugs, including Prozac.
This can lead to higher levels of Prozac in your bloodstream, increasing the risk of Prozac side effects like nausea, dizziness, insomnia, and more severe reactions.
While the combination of Prozac and marijuana isn’t inherently dangerous for everyone, it carries significant risks that shouldn’t be ignored. Everyone has different risk factors; the best way to explore yours is to speak with a healthcare professional.
That said, there are plenty of reasons to avoid cannabis if you’re dealing with mental health conditions. Cannabinoids can exacerbate depressive disorders and anxiety, and cannabis is a big red flag for people living with schizophrenia.
Further, using Prozac and weed in tandem at regular intervals may cause your body to accumulate SSRIs like Prozac, which could lead to issues down the road.
Still, that’s not necessarily a dealbreaker — particularly if your individual mental health care needs are being effectively met by Prozac and you feel your cannabis use has a positive effect on your mental health. After all, studies suggest that marijuana can help alleviate symptoms of anxiety and depression in some cases.
On the surface, Prozac and marijuana may not seem like risky drugs, given their widespread use and efficacy for various health-related needs. Put them together, however, and studies suggest this can be a recipe for disaster.
Prozac and weed don’t necessarily mix well. Because both substances affect the central nervous system, but in different ways, they can lead to additive effects and changes to your mood and brain. There’s also the risk of developing serotonin syndrome and an altered drug metabolism.
Not everyone will experience adverse effects. Still, we practice a better-safe-than-sorry approach, especially when it comes to mixing compounds in our bodies. It’s important to be aware of the potential risks of using Prozac and marijuana together before doing so.
Involving your healthcare provider is key. It’s always best to talk to your healthcare provider for medical advice and be upfront about any substance use — especially given that drug interactions can be serious. If you’re worried about the risks of mixing Prozac and weed, consider discussing the possibility of psychotherapy rather than medication.
To connect with one of our online healthcare providers, start by taking our free online assessment.
Hims & Hers has strict sourcing guidelines to ensure our content is accurate and current. We rely on peer-reviewed studies, academic research institutions, and medical associations. We strive to use primary sources and refrain from using tertiary references. See a mistake? Let us know at [email protected]!
Dr. Daniel Z. Lieberman is the senior vice president of mental health at Hims & Hers and of psychiatry and behavioral sciences at George Washington University. Prior to joining Hims & Hers, Dr. Lieberman spent over 25 years as a full time academic, receiving multiple awards for teaching and research. While at George Washington, he served as the chairman of the university’s Institutional Review Board and the vice chair of the Department of Psychiatry and Behavioral Sciences.
Dr. Lieberman’s has focused on , , , and to increase access to scientifically-proven treatments. He served as the principal investigator at George Washington University for dozens of FDA trials of new medications and developed online programs to help people with , , and . In recognition of his contributions to the field of psychiatry, in 2015, Dr. Lieberman was designated a distinguished fellow of the American Psychiatric Association. He is board certified in psychiatry and addiction psychiatry by the American Board of Psychiatry and Neurology.
As an expert in mental health, Dr. Lieberman has provided insight on psychiatric topics for the U.S. Department of Health and Human Services, U.S. Department of Commerce, and Office of Drug & Alcohol Policy.
Dr. Lieberman studied the Great Books at St. John’s College and attended medical school at New York University, where he also completed his psychiatry residency. He is the coauthor of the international bestseller , which has been translated into more than 20 languages and was selected as one of the “Must-Read Brain Books of 2018” by Forbes. He is also the author of . He has been on and to discuss the role of the in human behavior, , and .
1992: M.D., New York University School of Medicine
1985: B.A., St. John’s College, Annapolis, Maryland
2022–Present: Clinical Professor, George Washington University Department of Psychiatry and Behavioral Sciences
2013–2022: Vice Chair for Clinical Affairs, George Washington University Department of Psychiatry and Behavioral Sciences
2010–2022: Professor, George Washington University Department of Psychiatry and Behavioral Sciences
2008–2017: Chairman, George Washington University Institutional Review Board
2022: Distinguished Life Fellow, American Psychiatric Association
2008–2020: Washingtonian Top Doctor award
2005: Caron Foundation Research Award
Lieberman, D. Z., Cioletti, A., Massey, S. H., Collantes, R. S., & Moore, B. B. (2014). Treatment preferences among problem drinkers in primary care. International journal of psychiatry in medicine, 47(3), 231–240. https://journals.sagepub.com/doi/10.2190/PM.47.3.d?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Lieberman, D. Z., Swayze, S., & Goodwin, F. K. (2011). An automated Internet application to help patients with bipolar disorder track social rhythm stabilization. Psychiatric services (Washington, D.C.), 62(11), 1267–1269. https://ps.psychiatryonline.org/doi/10.1176/ps.62.11.pss6211_1267?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Lieberman, D. Z., Massey, S. H., & Goodwin, F. K. (2010). The role of gender in single vs married individuals with bipolar disorder. Comprehensive psychiatry, 51(4), 380–385. https://www.sciencedirect.com/science/article/abs/pii/S0010440X0900128X?via%3Dihub
Lieberman, D. Z., Kolodner, G., Massey, S. H., & Williams, K. P. (2009). Antidepressant-induced mania with concomitant mood stabilizer in patients with comorbid substance abuse and bipolar disorder. Journal of addictive diseases, 28(4), 348–355. https://pubmed.ncbi.nlm.nih.gov/20155604
Lieberman, D. Z., Montgomery, S. A., Tourian, K. A., Brisard, C., Rosas, G., Padmanabhan, K., Germain, J. M., & Pitrosky, B. (2008). A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. International clinical psychopharmacology, 23(4), 188–197. https://journals.lww.com/intclinpsychopharm/abstract/2008/07000/a_pooled_analysis_of_two_placebo_controlled_trials.2.aspx